Histamine, polyamines, and cancer.

Mammalian ornithine decarboxylase and histidine decarboxylase present common structural and functional features, and their products also share pharmacological and physiological properties. Although accumulated evidence pointed for years to a direct involvement of polyamines and histamine in tumour growth, it has been only in the last few years that new molecular data have contributed to the clarification of this topic. The aim of this commentary is to review the molecular grounds of the role of histamine and polyamines in cancer and to point to possible directions for future research in emerging areas of interest.

[1]  G. Kahlson.  New Approaches to the Physiology of Histamine , 2015, Physiological reviews.

[2]  H. Ohtsu,et al.  Identification of multiple regulatory elements of human L-histidine decarboxylase gene. , 1997, Journal of biochemistry.

[3]  H. Kiyosawa,et al.  Ornithine decarboxylase overexpression in mouse 10T1/2 fibroblasts: cellular transformation and invasion. , 1997, Journal of the National Cancer Institute.

[4]  A. Ichikawa,et al.  Enhanced expression of the mouse L-histidine decarboxylase gene with a combination of dexamethasone and 12-O-tetradecanoylphorbol-13-acetate. , 1993, Biochemical and biophysical research communications.

[5]  C. Kahana,et al.  Exposure to ornithine results in excessive accumulation of putrescine and apoptotic cell death in ornithine decarboxylase overproducing mouse myeloma cells. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[6]  A. Ichikawa,et al.  Degradation of the 74 kDa form of l‐histidine decarboxylase via the ubiquitin‐proteasome pathway in a rat basophilic/mast cell line (RBL‐2H3) , 1997, FEBS letters.

[7]  M Joshi,et al.  The importance of L-arginine metabolism in melanoma: an hypothesis for the role of nitric oxide and polyamines in tumor angiogenesis. , 1997, Free radical biology & medicine.

[8]  S. Matsufuji,et al.  Ornithine decarboxylase antizyme: a novel type of regulatory protein. , 1996, Trends in biochemical sciences.

[9]  Y. Endo.  Induction of histidine and ornithine decarboxylase activities in mouse tissues by recombinant interleukin-1 and tumor necrosis factor. , 1989, Biochemical pharmacology.

[10]  R. Möllby,et al.  OCCURRENCE OF P-FIMBRIATED ESCHERICHIA COLI IN URINARY TRACT INFECTIONS , 1981, The Lancet.

[11]  L. Andersson,et al.  Ornithine decarboxylase activity is critical for cell transformation , 1992, Nature.

[12]  F S LaBella,et al.  Enhanced cancer growth in mice administered daily human-equivalent doses of some H1-antihistamines: predictive in vitro correlates. , 1994, Journal of the National Cancer Institute.

[13]  H Hayashi,et al.  Pyridoxal enzymes: mechanistic diversity and uniformity. , 1995, Journal of biochemistry.

[14]  D. Maurice,et al.  Stimulation of neovascularization of the cornea by biogenic amines. , 1969, Experimental eye research.

[15]  I. Das,et al.  Inhibition of nitric oxide synthase by L-arginine metabolites. , 1995, Biochemical Society transactions.

[16]  C. Davio,et al.  Histamine receptors in an experimental mammary carcinoma. , 1994, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[17]  F. Sánchez-Jiménez,et al.  Experimental evidence for structure-activity features in common between mammalian histidine decarboxylase and ornithine decarboxylase. , 1996, The Biochemical journal.

[18]  S. Rogers,et al.  PEST sequences and regulation by proteolysis. , 1996, Trends in biochemical sciences.

[19]  K. Norrby.  Evidence of a dual role of endogenous histamine in angiogenesis. , 1995, International journal of experimental pathology.

[20]  E. Masini,et al.  Interaction between histamine and nitric oxide in rat mast cells and in isolated guinea pig hearts. , 1997, International archives of allergy and immunology.

[21]  D. Reis,et al.  Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. , 1996, The Biochemical journal.

[22]  F. LaBella,et al.  Enhancement of tumor growth by drugs with some common molecular actions , 1996, Molecular carcinogenesis.

[23]  T. Wang,et al.  Gastrin regulates the human histidine decarboxylase promoter through an AP-1-dependent mechanism. , 1997, The American journal of physiology.

[24]  M. Auvinen.  Cell transformation, invasion, and angiogenesis: a regulatory role for ornithine decarboxylase and polyamines? , 1997, Journal of the National Cancer Institute.

[25]  C. Zahnow,et al.  Characterization and expression of the complementary DNA encoding rat histidine decarboxylase. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Fraser Ra,et al.  Role of mast cells in experimental tumour angiogenesis. , 1983 .

[27]  M. Hackert,et al.  Structural motifs for pyridoxal‐5′‐phosphate binding in decarboxylases: An analysis based on the crystal structure of the Lactobacillus 30a ornithine decarboxylase , 1995, Protein science : a publication of the Protein Society.

[28]  C. Franceschi,et al.  Involvement of ornithine decarboxylase and polyamines in glucocorticoid-induced apoptosis of rat thymocytes. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[29]  L. Andersson,et al.  Human ornithine decarboxylase-overproducing NIH3T3 cells induce rapidly growing, highly vascularized tumors in nude mice. , 1997, Cancer research.

[30]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[31]  P. Peristeris,et al.  Evidence that nitric oxide is an endogenous antiangiogenic mediator , 1994, British journal of pharmacology.

[32]  M. García-Caballero,et al.  Histamine in Normal and Cancer Cell Proliferation , 1993 .

[33]  K. Yamauchi,et al.  Structure of the L-histidine decarboxylase gene. , 1994, The Journal of biological chemistry.

[34]  F. Sánchez-Jiménez,et al.  Regulation by 1,4-diamines of the ornithine decarboxylase activity induced by ornithine in perifused tumor cells. , 1991, Biochemical pharmacology.

[35]  C. Shayo,et al.  Histamine modulates the expression of c-fos through cyclic AMP production via the H2 receptor in the human promonocytic cell line U937. , 1997, Molecular pharmacology.

[36]  P. McCann,et al.  Ornithine decarboxylase as an enzyme target for therapy. , 1992, Pharmacology & therapeutics.

[37]  F. Sánchez-Jiménez,et al.  Mammalian L-amino acid decarboxylases producing 1,4-diamines: analogies among differences. , 1994, Trends in biochemical sciences.

[38]  J. Fozard,et al.  Role of histamine in tumor development , 1985 .